fda gsk - Search News

News

GSK shares fall

Reuters on MSN · 15h

GSK shares fall after blood cancer drug likely headed for U.S. rejection

(Reuters) -GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects. The British drugmaker was trying to revive the drug,

Bloomberg on MSN · 16h

GSK Falls After FDA Advisory Panel Fails to Back Cancer Drug

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

Financial Times · 14h

GSK blood cancer drug fails to win backing of key US regulatory panel

GSK has failed to win the backing of influential advisers to the US drugs regulator for a key blood cancer drug, putting its approval in doubt and sending shares in the pharmaceutical group 7 per cent lower on Friday morning.

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

GlobalData on MSN13h

FDA approves GSK’s prefilled syringe presentation of Shingrix

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results